# Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/interferon-alfa-2b-adjuvant-therapy-of-high-risk-resected-cutaneous-melanoma-the/

## Facts

| Field | Value |
| --- | --- |
| Author Names | J M Kirkwood,M H Strawderman,Marc S. Ernstoff,Thomas J. Smith,E C Borden,Ronald H. Blum |
| Citations | 2,106 |
| DOI | 10.1200/jco.1996.14.1.7 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1828940258 |
| PMID | 8558223 |
| Type | article |
| Year | 1996 |

## Paper authors

- [Thomas J. Smith](https://scholariq.org/researchers/thomas-j-smith/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)

## Paper topics

- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.